RNA (Atrium Therapeutics) Short Percentage of Float


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RNA vs RNAC, KROS, ARCT: Short Percentage of Float Comparison

For the Biotechnology subindustry, Atrium Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's Short Percentage of Float falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price